GOSS compared with INAB: revenue, margins and what each company keeps, and the suppliers and customers both name

GOSSGossamer Bio, Inc.

Mkt capRevenueRevenue

INABIN8BIO, Inc.

Mkt capRevenueRevenue

Compare

GOSSGossamer Bio, Inc.

INABIN8BIO, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

GOSS, solidINAB, dashed

Supply-chain overlap

Revenue flow

GOSS: latest quarter not drawable. INAB: latest quarter not drawable.Method ›

GOSSGossamer Bio, Inc.

10.35▼−3.17%· post 10.20

Mkt cap$63.4MRevenue$9MQ2 FY26Revenue$48MFY25

INABIN8BIO, Inc.

0.94▼−4.09%· post 0.94

ClosedOct 30 '26

Mkt cap$8.9MRevenue—Revenue—

Compare

ClosedOct 30 '26

GOSSGossamer Bio, Inc.

INABIN8BIO, Inc.

10.35▼−3.17%post 10.20

Price

0.94▼−4.09%post 0.94

$63.4M

Mkt cap

$8.9M

Q2 FY26$9M

Revenue

—

FY25$48M

Revenue

—

GOSS10.35▼−3.17%vsINAB0.94▼−4.09%ClosedOct 30 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GOSS 3

—Chiesiunlistedcustomer

—Pulmokineunlistedsupplier

—Respira Therapeuticsunlistedsupplier

Shared 0

No disclosed counterparties: INAB.

Only INAB 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR